机译:177年177年的神经内分泌肿瘤的安全性和结果:澳大利亚新南威尔士州的经验
Cancer Institute NSWSydney New South Wales Australia;
Cancer Institute NSWSydney New South Wales Australia;
Cancer Institute NSWSydney New South Wales Australia;
Cancer Institute NSWSydney New South Wales Australia;
Department of Nuclear Medicine Royal North Shore HospitalSydney New South Wales Australia;
Department of Nuclear Medicine St George HospitalSydney New South Wales Australia;
Department of Nuclear Medicine St George HospitalSydney New South Wales Australia;
Department of Nuclear Medicine Royal North Shore HospitalSydney New South Wales Australia;
Agency for Clinical InnovationSydney New South Wales Australia;
Cancer Institute NSWSydney New South Wales Australia;
neuroendocrine tumour; peptide receptor radionuclide therapy (PRRT); 177 Lu‐DOTATATE; radiopharmaceutical; clinical protocol;
机译:177年177年的神经内分泌肿瘤的安全性和结果:澳大利亚新南威尔士州的经验
机译:Lu-177-DOTATATE与Lu-177-EDTMP与鸡尾酒/序贯疗法在甲状腺髓样癌和神经内分泌肿瘤的骨限制性疼痛转移性疾病中的应用:可以半定量比较Ga-68-DOTATATE和F-18-氟化物PET- CT在选择最佳治疗方案时是否有助于个性化治疗决策?
机译:Lu-177-Dotatate治疗神经内分泌肿瘤的患者,包括高档(G3)神经内分泌肿瘤:对治疗和长期存活更新的反应
机译:〜(177)Lu-DOTA-J591单克隆抗体:化学,毒性,剂量和临床疗效:使用〜(177)LU-J591抗-PSMA抗体的前列腺癌
机译:177Lu标记的金纳米粒子用于局部晚期乳腺癌的放射治疗。
机译:90Y-DOTATATE和90Y / 177Lu-DOTATATE放射性核素治疗神经内分泌肿瘤的临床结果:哪种治疗方法更好?
机译:90Y-DOTATATE和90Y / 177Lu-DOTATATE放射核素治疗神经内分泌肿瘤的临床结果:哪种治疗方法更好?